2005 Tuberculosis Drug Development Gordon Conference

第三届戈登结核病药物开发会议将于2005年7月3日至7月8日在新罕布夏州梅里登的金博尔联合学院举行。第一次会议 2001年在新伦敦科尔比-索耶学院举行。这次会议取得了巨大的成功，因为它开始通过公开讨论确定了人类的化学和生物活动 来自结核分枝杆菌的大分子有可能成为药物靶标。2003年的会议 在该领域取得了重大进展，因为2001年提出的许多目标都得到了验证，并在2003年之前在药物发现方案中得到了验证。这一领域甚至取得了进一步的进展，现在有几个靶点带有抑制剂，这些靶点是先导优化和临床前试验。 2005年会议的主要重点将是进一步促进结核病药物发现方面的研究。我们已经计划了9次大致与药物发现过程同时进行的会议(即， 目标选择到临床试验)。2005年会议的一个主题将是治疗新药。 耐药、持久和潜伏的结核分枝杆菌感染。

The third Gordon Conference in Tuberculosis Drug Development will be held at Kimball Union Academy, Meriden New Hampshire, from July 3, 2005 to July 8, 2005. The first conference was held at Colby-Sawyer College New London, NH in 2001. The meeting was a great success as it began to define, through open discussion, the chemistry and biological activities of macromolecules from M. tuberculosis that had potential as being drug targets. The 2003 meeting showed significant advances in the field, as many of the targets proposed in 2001, were validated and in drug discovery programs by 2003. The field has advanced even further and there are now several targets with inhibitors in that are lead optimization and pre-clinical trials. The main focus of the 2005 meeting will be to further stimulate research in TB drug discovery. We have planned 9 sessions that roughly coincided with the drug discovery process (ie, target selection to clinical trials). A theme of the 2005 conference will be on new drugs to treat drug-resistant, persistent and latent M. tuberculosis infections.